Benjamin Garmezy, MD, on JNJ-6143, a first-in-class oral AR-targeted RIPTAC™, at the optimal dose in metastatic prostate cancer, including high-risk molecular features. #ESMO26

Watch now: https://bit.ly/4dYJ1dp